This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.

You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/business/7352967.stm

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Generic competition hits Pfizer Generic competition hits Pfizer
(about 7 hours later)
US drugs giant Pfizer posted an 18% drop in profits for the first three months of 2008 after competition from cheaper patent free products.US drugs giant Pfizer posted an 18% drop in profits for the first three months of 2008 after competition from cheaper patent free products.
The New York-based firm's net income fell to $2.78bn (£1.4bn), from $3.39bn in the January to March period.The New York-based firm's net income fell to $2.78bn (£1.4bn), from $3.39bn in the January to March period.
It blamed the loss of US patent protection to sell blockbuster blood-pressure drug Norvasc and allergy relief medicine Zyrtec.It blamed the loss of US patent protection to sell blockbuster blood-pressure drug Norvasc and allergy relief medicine Zyrtec.
The loss of exclusivity for key drugs is a concern across the sector.The loss of exclusivity for key drugs is a concern across the sector.
Pfizer also nursed a worse-than-expected sales decline of flagship cholesterol fighter Lipitor, which generated $300m less revenue than some analysts were expecting.Pfizer also nursed a worse-than-expected sales decline of flagship cholesterol fighter Lipitor, which generated $300m less revenue than some analysts were expecting.
It insisted that it would meet its previously stated profit targets for the year, helped by a massive cost-cutting programme that has already seen 10,000 jobs go.It insisted that it would meet its previously stated profit targets for the year, helped by a massive cost-cutting programme that has already seen 10,000 jobs go.
The firm's poor performance came despite a boost from the weak dollar which makes sales abroad more valuable.The firm's poor performance came despite a boost from the weak dollar which makes sales abroad more valuable.
Shares in the company dropped 3.3% to $20.4, topping the losers on the benchmark Dow Jones index, which was down less than 0.5% in midday trade in New York. Shares in the company dropped 3.3% to $20.4, topping the losers on the benchmark Dow Jones index, which closed virtually unchanged in New York, up 1.2 points.